139 related articles for article (PubMed ID: 30383653)
1. Influence of an inconsistent appearance of antipsychotics on drug adherence in patients with schizophrenia.
Lertxundi U; Hernandez R; Corcóstegui B; Ibarra O; Mentxaka G; Medrano J
Medicine (Baltimore); 2018 Nov; 97(44):e12990. PubMed ID: 30383653
[TBL] [Abstract][Full Text] [Related]
2. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder.
Greene M; Yan T; Chang E; Hartry A; Touya M; Broder MS
J Med Econ; 2018 Feb; 21(2):127-134. PubMed ID: 28895758
[TBL] [Abstract][Full Text] [Related]
3. Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients.
Ascher-Svanum H; Peng X; Faries D; Montgomery W; Haddad PM
BMC Psychiatry; 2009 Jul; 9():46. PubMed ID: 19640279
[TBL] [Abstract][Full Text] [Related]
4. Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia.
Offord S; Lin J; Mirski D; Wong B
Adv Ther; 2013 Mar; 30(3):286-97. PubMed ID: 23483449
[TBL] [Abstract][Full Text] [Related]
5. Antipsychotics Use Is Associated With Greater Adherence to Cardiometabolic Medications in Patients With Schizophrenia: Results From a Nationwide, Within-subject Design Study.
Solmi M; Tiihonen J; Lähteenvuo M; Tanskanen A; Correll CU; Taipale H
Schizophr Bull; 2022 Jan; 48(1):166-175. PubMed ID: 34286338
[TBL] [Abstract][Full Text] [Related]
6. Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence.
Si T; Li N; Lu H; Cai S; Zhuo J; Correll CU; Zhang L; Feng Y
J Psychopharmacol; 2018 Jun; 32(6):691-701. PubMed ID: 29764266
[TBL] [Abstract][Full Text] [Related]
7. Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data.
Yan T; Greene M; Chang E; Hartry A; Touya M; Broder MS
Adv Ther; 2018 Oct; 35(10):1612-1625. PubMed ID: 30206822
[TBL] [Abstract][Full Text] [Related]
8. Association between community pharmacy loyalty and persistence and implementation of antipsychotic treatment among individuals with schizophrenia.
Zongo FE; Moisan J; Grégoire JP; Lesage A; Dossa AR; Lauzier S
Res Social Adm Pharm; 2018 Jan; 14(1):53-61. PubMed ID: 28077240
[TBL] [Abstract][Full Text] [Related]
9. Should antipsychotic medications for schizophrenia be given for a lifetime? Replication of a naturalistic, long-term, follow-up study of antipsychotic treatment.
Glick ID; Zamora D; Kamis D; Davis JM
CNS Spectr; 2019 Oct; 24(5):557-563. PubMed ID: 30777584
[TBL] [Abstract][Full Text] [Related]
10. Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics.
Shah A; Xie L; Kariburyo F; Zhang Q; Gore M
Adv Ther; 2018 Nov; 35(11):1994-2014. PubMed ID: 30269292
[TBL] [Abstract][Full Text] [Related]
11. Estimating the Impact of Adherence to and Persistence with Atypical Antipsychotic Therapy on Health Care Costs and Risk of Hospitalization.
Jiang Y; Ni W
Pharmacotherapy; 2015 Sep; 35(9):813-22. PubMed ID: 26406773
[TBL] [Abstract][Full Text] [Related]
12. Real-world adherence assessment of lurasidone and other oral atypical antipsychotics among patients with schizophrenia: an administrative claims analysis.
Rajagopalan K; Wade S; Meyer N; Loebel A
Curr Med Res Opin; 2017 May; 33(5):813-820. PubMed ID: 28098496
[TBL] [Abstract][Full Text] [Related]
13. Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention.
Agid O; Foussias G; Remington G
Expert Opin Pharmacother; 2010 Oct; 11(14):2301-17. PubMed ID: 20586707
[TBL] [Abstract][Full Text] [Related]
14. A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia.
Ascher-Svanum H; Zhu B; Faries D; Lacro JP; Dolder CR
J Clin Psychiatry; 2006 Jul; 67(7):1114-23. PubMed ID: 16889456
[TBL] [Abstract][Full Text] [Related]
15. Do Long-Acting Injectable Antipsychotics Prevent or Delay Hospital Readmission?
Maestri TJ; Mican LM; Rozea H; Barner JC
Psychopharmacol Bull; 2018 Mar; 48(3):8-15. PubMed ID: 29713100
[TBL] [Abstract][Full Text] [Related]
16. Measuring adherence to medication in schizophrenia: the relationship between attitudes toward drug therapy and plasma levels of new-generation antipsychotics.
Yalcin-Siedentopf N; Wartelsteiner F; Kaufmann A; Biedermann F; Edlinger M; Kemmler G; Rettenbacher MA; Widschwendter CG; Zernig G; Fleischhacker WW; Hofer A
Int J Neuropsychopharmacol; 2014 Dec; 18(5):. PubMed ID: 25522423
[TBL] [Abstract][Full Text] [Related]
17. Adherence to clozapine vs. other antipsychotics in schizophrenia.
Takeuchi H; Borlido C; Sanches M; Teo C; Harber L; Agid O; Remington G
Acta Psychiatr Scand; 2020 Aug; 142(2):87-95. PubMed ID: 32627168
[TBL] [Abstract][Full Text] [Related]
18. Adherence to Oral Antipsychotics Measured by Electronic Adherence Monitoring in Schizophrenia: A Systematic Review and Meta-analysis.
Yaegashi H; Kirino S; Remington G; Misawa F; Takeuchi H
CNS Drugs; 2020 Jun; 34(6):579-598. PubMed ID: 32219681
[TBL] [Abstract][Full Text] [Related]
19. Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics.
Pilon D; Alcusky M; Xiao Y; Thompson-Leduc P; Lafeuille MH; Lefebvre P; Benson C
J Med Econ; 2018 Feb; 21(2):135-143. PubMed ID: 28895766
[TBL] [Abstract][Full Text] [Related]
20. Adherence to antipsychotics and cardiometabolic medication: association with health care utilization and costs.
Hansen RA; Maciejewski M; Yu-Isenberg K; Farley JF
Psychiatr Serv; 2012 Sep; 63(9):920-8. PubMed ID: 22706887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
